An Unsurprising Pipeline Failure

Eli Lilly pulls the plug on this pipeline program.

Brenton Flynn
Brenton Flynn
Feb 8, 2013 at 12:00PM
Health Care

Eli Lilly (NYSE:LLY) announced yesterday that it would be ending its rheumatoid arthritis program for its drug tabalumab. In December, Lilly ended one of its three trials for this drug because it was showing no benefit, and it's now ended the other two trials for similar reasons. In the video, Brenton tells us about the drug's other potential application in the lupus space, and some other pipeline candidates it will be falling back on as it tries to gain share in the lucrative arthritis market.